Unified Junction of Care, Integrated Treatments and Team Coordination for ADHD in Prison Settings With Substance Use Disorder (JUSTICE-TDAH)

August 7, 2026 updated by: University Hospital, Brest
Substance use disorders (SUD) and attention deficit disorder with or without hyperactivity (ADHD) are frequently co-morbid, particularly among people under court supervision. The coexistence of these disorders increases the social and legal vulnerability of individuals. Better identification of ADHD in vulnerable people with SUD is essential to improving their care. This project aims to provide appropriate support for this at-risk population.

Study Overview

Status

Recruiting

Conditions

Intervention / Treatment

Study Type

Interventional

Enrollment (Estimated)

39

Phase

  • Not Applicable

Contacts and Locations

This section provides the contact details for those conducting the study, and information on where this study is being conducted.

Study Contact

Study Locations

  • France
      • Brest, France, 29200
        • Recruiting
        • CHU Brest
        • Contact:
        • Principal Investigator:
          • Morgane GUILLOU LANDREAT, MD

Participation Criteria

Researchers look for people who fit a certain description, called eligibility criteria. Some examples of these criteria are a person's general health condition or prior treatments.

Eligibility Criteria

Ages Eligible for Study

  • Adult
  • Older Adult

Accepts Healthy Volunteers

No

Description

Inclusion Criteria:

  • Adult, under the supervision of the justice system or monitored by a correctional facility
  • Diagnosis of Substance Use Disorder (SUD)
  • Diagnosis of Attention Deficit Hyperactivity Disorder (ADHD)
  • No objection from the patient
  • Affiliated with a Social Security system

Exclusion Criteria:

  • Severe or decompensated psychiatric disorders
  • Severe cognitive impairment
  • Lack of understanding of the French language
  • Refusal to participate

Study Plan

This section provides details of the study plan, including how the study is designed and what the study is measuring.

How is the study designed?

Design Details

  • Primary Purpose: Supportive Care
  • Allocation: N/A
  • Interventional Model: Single Group Assignment
  • Masking: None (Open Label)

Arms and Interventions

Participant Group / Arm
Intervention / Treatment
Experimental: Workshops
Workshops with a small group of patients.
Other: Workshop
Assess the 5 workshops, co-constructed by the scientific committee and thanks to feedback from the qualitative study

What is the study measuring?

Primary Outcome Measures

Outcome Measure
Measure Description
Time Frame
80% of patients participated in the workshops
Time Frame: From enrollment to the end of wordshop at 6 months

The primary outcome measure is the acceptability of the program to participants in the pilot workshops, gathered through:

  • Semi-structured pre- and post-intervention interviews
  • A Likert scale
  • Workshop participation rate (at least 80%)
From enrollment to the end of wordshop at 6 months

Secondary Outcome Measures

Outcome Measure
Measure Description
Time Frame
SF-12 quality of life
Time Frame: From enrollment to the end of wordshop at 6 months
The secondary outcome measure will be measured by the SF-12 quality of life, before and after the 5 workshops. The SF-12 is a self-reported outcome measure assessing the impact of health on an individual's everyday life.
From enrollment to the end of wordshop at 6 months

Collaborators and Investigators

This is where you will find people and organizations involved with this study.

Sponsor

University Hospital, Brest

Investigators

  • Principal Investigator: Morgane GUILLOU-LANDREAT, MD, CHU Brest

Study record dates

These dates track the progress of study record and summary results submissions to ClinicalTrials.gov. Study records and reported results are reviewed by the National Library of Medicine (NLM) to make sure they meet specific quality control standards before being posted on the public website.

Study Major Dates

Study Start (Actual)

August 3, 2026

Primary Completion (Estimated)

January 1, 2028

Study Completion (Estimated)

January 1, 2028

Study Registration Dates

First Submitted

March 12, 2026

First Submitted That Met QC Criteria

March 17, 2026

First Posted (Actual)

March 23, 2026

Study Record Updates

Last Update Posted (Actual)

August 11, 2026

Last Update Submitted That Met QC Criteria

August 7, 2026

Last Verified

August 1, 2026

More Information

Terms related to this study

Additional Relevant MeSH Terms

Other Study ID Numbers

  • 29BRC25.0324 - JUSTICE-TDAH
  • IDRCB (Other Identifier: 2025-A02589-40)

Plan for Individual participant data (IPD)

Plan to Share Individual Participant Data (IPD)?

YES

IPD Plan Description

All collected data that underlie results in a publication

IPD Sharing Time Frame

Data will be available after the publication of result and ending fifteen years following the last visit of the last patient.

IPD Sharing Access Criteria

Data access requests will be reviewed by the internal committee of BrestUH. Requestors will be required to sign and complete a data access agreement.

IPD Sharing Supporting Information Type

  • STUDY_PROTOCOL

Drug and device information, study documents

Studies a U.S. FDA-regulated drug product

No

Studies a U.S. FDA-regulated device product

No

This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.

Subscribe